| Market Cap | 415.82B | P/E | 33.55 | EPS this Y | 5.00% | Ern Qtrly Grth | - |
| Income | 12.72B | Forward P/E | 14.55 | EPS next Y | 3.20% | 50D Avg Chg | - |
| Sales | 96.26B | PEG | 3.46 | EPS past 5Y | 5.79% | 200D Avg Chg | -3.00% |
| Dividend | 3.00% | Price/Book | 5.87 | EPS next 5Y | 4.34% | 52W High Chg | -13.00% |
| Recommedations | 2.40 | Quick Ratio | 0.68 | Shares Outstanding | 2.60B | 52W Low Chg | 7.00% |
| Insider Own | 0.10% | ROA | 8.69% | Shares Float | 2.60B | Beta | 0.53 |
| Inst Own | 71.73% | ROE | 17.48% | Shares Shorted/Prior | 13.48M/14.07M | Price | 160.01 |
| Gross Margin | 66.98% | Profit Margin | 13.22% | Avg. Volume | 7,186,330 | Target Price | 179.71 |
| Oper. Margin | 27.03% | Earnings Date | Jul 20 | Volume | 5,132,932 | Change | -0.16% |
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
| Mizuho | Buy | Jun 7, 23 |
| Atlantic Equities | Neutral | Apr 19, 23 |
| Morgan Stanley | Equal-Weight | Apr 19, 23 |
| Raymond James | Outperform | Apr 19, 23 |
| Morgan Stanley | Equal-Weight | Apr 10, 23 |
| UBS | Neutral | Mar 29, 23 |
| Guggenheim | Neutral | Mar 1, 23 |
| Cantor Fitzgerald | Overweight | Feb 1, 23 |
| Morgan Stanley | Equal-Weight | Jan 25, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Swanson James D. | See Remarks See Remarks | Mar 06 | Sell | 154.6600 | 1,062 | 164,199 | 9,215 | 03/08/23 |
| McEvoy Ashley | EVP, WW Chair, MedTe.. EVP, WW Chair, MedTech | Nov 30 | Option | 72.54 | 73,323 | 5,318,850 | 115,136 | 12/02/22 |
| McEvoy Ashley | EVP, WW Chair, MedTe.. EVP, WW Chair, MedTech | Nov 30 | Sell | 175.77 | 73,323 | 12,887,984 | 41,813 | 12/02/22 |
| Wengel Kathryn E | EVP, Chief GSC Offic.. EVP, Chief GSC Officer | Nov 09 | Option | 72.54 | 16,410 | 1,190,381 | 87,721 | 11/10/22 |
| Wengel Kathryn E | EVP, Chief GSC Offic.. EVP, Chief GSC Officer | Nov 09 | Sell | 173.42 | 16,410 | 2,845,822 | 71,311 | 11/10/22 |
| Mongon Thibaut | Exec VP, WW Chair, C.. Exec VP, WW Chair, Consumer | Nov 07 | Option | 108.77 | 17,043 | 1,853,767 | 57,176 | 11/09/22 |
| Mongon Thibaut | Exec VP, WW Chair, C.. Exec VP, WW Chair, Consumer | Nov 04 | Option | 130.73 | 35,246 | 4,607,710 | 75,379 | 11/08/22 |
| Mongon Thibaut | Exec VP, WW Chair, C.. Exec VP, WW Chair, Consumer | Nov 04 | Sell | 171.18 | 35,246 | 6,033,410 | 40,133 | 11/08/22 |
| Wengel Kathryn E | EVP, Chief GSC Offic.. EVP, Chief GSC Officer | Jun 10 | Sell | 173 | 40,000 | 6,920,000 | 71,311 | 06/14/22 |
| Wengel Kathryn E | EVP, Chief GSC Offic.. EVP, Chief GSC Officer | Jun 10 | Option | 72.54 | 40,000 | 2,901,600 | 111,311 | 06/14/22 |
| Decker Robert J | Controller, CAO Controller, CAO | May 26 | Option | 72.54 | 8,462 | 613,833 | 23,935 | 05/31/22 |
| Decker Robert J | Controller, CAO Controller, CAO | May 26 | Sell | 180 | 8,462 | 1,523,160 | 15,473 | 05/31/22 |
| Hait William | See Remarks See Remarks | Apr 21 | Option | 90.44 | 29,699 | 2,685,978 | 109,935 | 04/25/22 |
| Hait William | See Remarks See Remarks | Apr 21 | Sell | 183.58 | 29,699 | 5,452,142 | 80,236 | 04/25/22 |
| Gorsky Alex | Director Director | Jan 14 | Option | 65.37 | 231,951 | 15,162,637 | 695,601 | 01/19/22 |
| Duato Joaquin | CEO CEO | Jan 14 | Option | 65.37 | 84,423 | 5,518,732 | 280,475 | 01/19/22 |
| Sneed Michael E | EVP, Global Corp Aff.. EVP, Global Corp Aff & COO | Dec 10 | Option | 62.2 | 54,662 | 3,399,976 | 110,741 | 12/10/20 |
| Sneed Michael E | EVP, Global Corp Aff.. EVP, Global Corp Aff & COO | Dec 10 | Sell | 152.93 | 54,662 | 8,359,460 | 56,079 | 12/10/20 |